Experts showcase next-gen biotech solutions to climate crisis
Industry experts have presented the latest biotech solutions for tackling climate change at the first INDUSTRIA BIOTEC conference, Europe’s new forum for the industrial biotech sector.
Author Archive for: TG
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 1300 entries already.
Entries by Thomas Gabrielczyk
Stalicla SA and Evgen Pharma plc ink $160.5m licensing deal for SFX-01
/in News/by Thomas GabrielczykPrecision neuroscience company Stalicla SA has licensed SFX-01 from Evgen Pharma plc in neurodevelopmental disorders and schizophrenia.
Clinical Microbiomics A/S bags 10m financing
/in News/by Thomas GabrielczykDanish microbiome specialist Clinical Microbiomics A/S has completed a 10m growth financing led by Seventure Partners.
EU starts largest study on factors affecting mental health
/in News/by Thomas GabrielczykThe EU Commission has granted £8.4m for Youth-GEMS, the largest ever study to identify genetic and other risks affecting mental health in adolescence.
Standing Ovation wins Industria Biotecs start-up pitch
/in News/by Thomas GabrielczykFrench Standing Ovation has won the start-up pitch of Industria Biotec, held for the first time in Berlin. The event presents biotechnological solutions to save the climate.
Araris Biotech closes $24m Series A financing round
/in News/by Thomas GabrielczykSwiss ADC maker Araris Biotech AG has added a $24m financing round to its CHF15.2m (S17.8m) seed round in 2020 to expand its portfolio of proprietary antibody drug conjugates.
New Protein Fund I supports 17 alternative protein start-ups
/in News/by Thomas GabrielczykWith money from its $50m New Protein Fund, Big Idea Ventures funds in 17 pre-seed plant-based, cell-based and microbial food, ingredient and technology companies.
Sibylla Biotech raises 23m Series A
/in News/by Thomas GabrielczykVerona-based Sibylla Biotech has closed a 23m Series A financing round to advance its Pharmacological Protein Inactivation by Folding Intermediate Targeting (PPI-FIT) platform.
AI expert XUND GmbH bags 6m seed financing
/in News/by Thomas GabrielczykAustrian XUND GmbH wants to use the assets of a 6m seed financing to grow in Germany, Switzerland and Austria.
ADC makeer Pheon Therapeutics raises $68m
/in News/by Thomas GabrielczykAntibody-Drug Conjugate (ADC) specialist Pheon Therapeutics Ltd. has closed a $68m Series A financing co-led by Brandon Capital, Forbion and Atlas Venture.